Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety Study of Stemchymal® (Allogeneic Adipose-Derived Mesenchymal Stem Cells) Treating on Acute Liver Failure - An Open-Label, Single-Center Phase I Trial

NCT03629015 is registered in ClinicalTrials.gov with Steminent Biotherapeutics Inc. as lead sponsor.

NCT NCT03629015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03629015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety Study of Stemchymal® (Allogeneic Adipose-Derived Mesenchymal Stem Cells) Treating on Acute Liver Failure - An Open-Label, Single-Center Phase I Trial
Lead sponsor
Steminent Biotherapeutics Inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
October 1, 2018
Completion date
May 18, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute liver failure, acute-on-chronic liver failure, adult stem cells, stem cells, steminent